Bloomberg Law
Sept. 28, 2017, 4:50 PM

AbbVie Settles Legal Fight Against Amgen Over Humira Copycat

Bloomberg Media

By Susan Decker and Cynthia Koons, Bloomberg News

AbbVie Inc. reached a deal with Amgen Inc. that will allow a copy of blockbuster arthritis drug Humira to be sold in Europe next year -- but a U.S. version won’t hit shelves until more than four years later.

Financial terms of the agreement weren’t disclosed. Amgen will pay AbbVie patent royalties when it begins sales of its drug, called Amgevita, in Europe on Oct. 16, 2018. The U.S. version, called Amjevita, will come to market on Jan. 31, 2023.

Settling with Amgen removes one possible legal threat for AbbVie, which gets ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.